Diaphragma sellae meningioma

Summary

Diaphragma sellae meningioma (MONDO:0004108) is a disease and 1 clinical trial. Top therapeutic interventions include bupivacaine and prilocaine. A subtype of sella turcica neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	diaphragma sellae meningioma
Mondo ID	MONDO:0004108
DOID	DOID:7103
NCIT	C5283
UMLS	C1333283
MedGen	234200
GARD	0023829
Anatomy (UBERON)	UBERON:0035416
Is cancer (heuristic)	no

Also known as: diaphragm sellae meningioma · diaphragma sellae meningioma (disease) · meningioma (disease) of diaphragma sellae · meningioma of diaphragm sellae · meningioma of Diaphragma sellae · meningioma of the diaphragm sellae · meningioma of the Diaphragma sellae

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › head and neck neoplasm › skull neoplasm › skull base neoplasm › sella turcica neoplasm › diaphragma sellae meningioma

Related subtypes (3): tuberculum sellae meningioma, pituitary tumor, craniopharyngioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04756050	PHASE4	COMPLETED	Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BUPIVACAINE	4	1
PRILOCAINE	4	1